Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-β1b-treated multiple sclerosis patients

Abstract

To identify immunological markers that could be used to monitor relapsing-remitting multiple sclerosis (RRMS) course/activity during interferon beta 1b (IFNβ1b) therapy, we longitudinally studied HLA-DR and CD25 expression by T lymphocytes in 15 IFNβ1b-treated RRMS patients. Peripheral blood T cell subsets were analysed before therapy (T0), and after 1 (T1), 2 (T2), 3 (T3), 6 (T4) and 12 (T5) months after therapy initiation. HLADR expression and the CD3+HLA-DR+ T cell number showed a peculiar trend in almost all (14/15) the patients: a significant decrease at T1 and T2 followed by a return to pre-treatment levels from T3 to T5. At T1 and T2, eight patients showed an up-regulation of CD25 on CD4, as well as an increase in the CD4+CD25+ cell number. However, a marked, significant reduction of this T cell subset was observed in all the patients at T3, followed by the progressive return to pre-treatment values from T4 to T5. All the patients developed anti-IFNβ1b `binding' antibodies within the first three months of therapy. Our findings demonstrate that: (1) the expression of HLA-DR and CD25 on T cells, as well as the number of circulating CD3+HLA-DR+ and CD4+CD25+ cells, are only transiently reduced in vivo in IFNβ1b-treated RRMS patients, (2) the expression of HLA-DR and CD25 on T lymphocytes cannot be used to monitor MS course/activity during IFNβ1b therapy, (3) the long-lasting beneficial effect of IFNβ1b on RRMS reported in the literature cannot be explained by the down-regulation of MHC class II antigens and/or interleukin-2 receptor expression induced by this cytokine.

Keywords

multiple sclerosis interferon beta 1b lymphocyte subsets HLA-DR CD4 CD25

Get full access to this article

View all access options for this article.

References

The IFNB Multiple Sclerosis Study Group . (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology 43: 655-661 .

Paty DW , Li DKB , the UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group . (1993) Interferon beta 1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology 43: 662-667 .

de Maeyer E , de Maeyer-Guignard J. (1991) Interferons. In: Thomson A (ed.). The cytokine handbook, Academic Press Ltd: New York , pp. 215-239.

Larocca AP , Borden EC , Colby CB. (1992) Human Interferon Beta. In: Aggarwal BB , Gutterman JU (eds). Human cytokines. Handbook for basic and clinical research, Blackwell Scientific Publication: London , pp. 17-29.

Wienstock-Guttman B , Ransohoff RM , Kinkel RP , Rudick RA. (1995) The interferons: biological effects, mechanisms of action, and use in multiple sclerosis . Ann Neurol 37: 7-15 .

Jacobs L , Johnson KP. (1994) A brief history of the use of interferons as treatment of multiple sclerosis . Arch Neurol 51: 1245-1252 .

Nohoronha A , Toscas A , Jensen MA. (1993) Interferon β decreases T cell activation and interferon γ production in multiple sclerosis . J Neuroimmunol 46: 145-154 .

Rudick RA et al. (1993) In vitro and in vivo inhibition of mitogen-driven T cell activation by recombinant inter-feron beta . Neurology 43: 2080-2087 .

Brod SA et al. (1996) Interferon-β1b treatment decreases tumor necrosis factor alpha and increases interleukin-6 production in multiple sclerosis . Neurology 46: 1633-1638 .

10.

Ling PD , Warren MK , Vogel SN. (1985) Antagonistic effect of interferon beta on the interferon gamma induced expression of la antigen in murine macrophages . J Immunol 135: 1857-1863 .

11.

Inaba K et al. (1986) Contrasting effects of alpha/beta and gamma-interferons on expression of macrophage la antigens . J Exp Med 163: 1030-1035 .

12.

Rudick RA et al. (1993) In vitro and in vivo inhibition of nitrogen-driven T-cell activation by recombinant inter-feron beta . Neurology 43: 2080-2087 .

13.

Leppert D et al. (1996) Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis . Ann Neurol 40: 846-852 .

14.

Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 13: 227-231 .

15.

Kurzke JF. (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 33: 1444-1452 .

16.

Larocca AP et al. (1989) Evaluation of neutralizing antibodies in patients treated with recombinant inter-feron-βser . J Interferon Res 9 (Suppl 1): S51-S60 .

17.

Dayal AS , Jensen MA , Lledo A , Arnason BGW. (1995) Interferon gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b . Neurology 45: 2173-2177 .

18.

Pette M et al. (1997) Interferon-β interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes . Neurology 49: 385-392 .

19.

Pachner AR. (1997) Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist . Neurology 49: 647-650 .